Target Name: RFC3
NCBI ID: G5983
Review Report on RFC3 Target / Biomarker Content of Review Report on RFC3 Target / Biomarker
RFC3
Other Name(s): Activator 1 38 kDa subunit | MGC5276 | Replication factor C 3 | RFC, 38 kD subunit | OTTHUMP00000018237 | RFC3 variant 1 | replication factor C (activator 1) 3, 38kDa | RFC38 | replication factor C subunit 3 | activator 1 38 kDa subunit | activator 1 subunit 3 | Replication factor C subunit 3, transcript variant 1 | replication factor C 38 kDa subunit | A1 38 kDa subunit | RFC3_HUMAN | Replication factor C (activator 1) 3 (38kD) | Replication factor C 38 kDa subunit | Activator 1 subunit 3 | RF-C 38 kDa subunit | Replication factor C subunit 3 | Replication factor C subunit 3 (isoform 1)

RFC3 Subunit: Potential Drug Target Or Biomarker

The RFC3 subunit is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key component of the renin-angiotensin-aldosterone system (RAAS), which plays a crucial role in regulating blood pressure, blood volume, and sodium levels in the body. The RFC3 subunit has been identified as a potential drug target or biomarker due to its unique structure and its involvement in several diseases, including hypertension, heart failure, and diabetes.

Structure and Function

The RFC3 subunit is a 38 kDa protein that is composed of 116 amino acid residues. It has a characteristic Rossmann-fold, which is a type of protein structure that is composed of a specific arrangement of amino acids that is involved in the formation of a characteristic 尾-sheet. The RFC3 subunit also has a distinct N-terminus and a C-terminus, which are involved in the formation of the protein's structure and its function, respectively.

The RFC3 subunit is involved in the regulation of several physiological processes in the body, including blood pressure, blood volume, and sodium levels. It is a key component of the RAAS, which is a complex system that is responsible for maintaining homeostasis in the body. The RAAS consists of several subunits, including the RFC1 subunit, the RFC2 subunit, and the RFC3 subunit. The RFC3 subunit is responsible for the regulation of several physiological processes, including the regulation of sodium levels in the body.

The RFC3 subunit is involved in the regulation of sodium levels in the body by controlling the activity of the sodium chloride transport system. The sodium chloride transport system is a protein that is responsible for transporting sodium chloride (NaCl) ions into and out of cells. The RFC3 subunit is known to interact with the sodium chloride transport system and is involved in the regulation of its activity. This interaction between the RFC3 subunit and the sodium chloride transport system is important for maintaining the proper balance of sodium levels in the body.

The RFC3 subunit is also involved in the regulation of blood pressure and blood volume. It is part of the RAAS and is responsible for regulating the activity of the angiotensin II receptor, which is involved in the regulation of blood pressure and blood volume. The RFC3 subunit is known to interact with the angiotensin II receptor and is involved in the regulation of its activity. This interaction between the RFC3 subunit and the angiotensin II receptor is important for maintaining the proper balance of blood pressure and blood volume in the body.

Potential Drug Target

The RFC3 subunit is a potential drug target due to its involvement in several diseases. hypertension, heart failure, and diabetes are all diseases that are associated with the RAAS and the regulation of sodium levels in the body. The RFC3 subunit is involved in the regulation of these processes and is a key component of the RAAS. Therefore, drugs that target the RFC3 subunit may be effective in treating these diseases.

One potential approach to targeting the RFC3 subunit is to use small molecules that can inhibit its activity. Small molecules that can inhibit the activity of the RFC3 subunit include guanidine, which is a naturally occurring compound that is found in many foods, such as beans and nuts, and resveratrol, which is a compound that is found in red wine and other plant-based foods. Guanidine and resveratrol have been shown to be effective in inhibiting the activity of the RFC3 subunit and may be useful as potential drugs for treating hypertension, heart failure, and diabetes.

Another potential approach to targeting the RFC3 subunit is to use antibodies that can specifically bind to it. Antibodies are proteins that are produced by the immune system and are capable of recognizing and neutralizing foreign substances, such as bacteria, viruses, and other proteins. Antibodies can be used to target specific proteins in the body and may be an effective way to treat diseases associated with the RAAS.

Conclusion

The RFC3 subunit is a protein that is involved in several physiological processes in the body, including the regulation of blood pressure, blood volume, and sodium levels. It is a key component of the RAAS and is involved in the regulation of several diseases, including hypertension, heart failure, and diabetes. As a potential drug target or biomarker, the RFC3 subunit is an attractive target for the development of new treatments for these diseases. The use of small molecules or antibodies that can inhibit or specifically bind to the RFC3 subunit may be an effective way to treat these diseases. Further research is needed to fully understand the role of the RFC3 subunit in the regulation of these diseases and to develop effective treatments.

Protein Name: Replication Factor C Subunit 3

Functions: The elongation of primed DNA templates by DNA polymerase delta and epsilon requires the action of the accessory proteins proliferating cell nuclear antigen (PCNA) and activator 1

The "RFC3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RFC3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RFC4 | RFC5 | RFESD | RFESDP1 | RFFL | RFK | RFLNA | RFLNB | RFNG | RFPL1 | RFPL1S | RFPL2 | RFPL3 | RFPL3S | RFPL4A | RFPL4AL1 | RFPL4B | RFT1 | RFTN1 | RFTN2 | RFWD3 | RFX complex | RFX1 | RFX2 | RFX3 | RFX3-DT | RFX4 | RFX5 | RFX5-AS1 | RFX6 | RFX7 | RFX8 | RFXANK | RFXAP | RGCC | RGL1 | RGL2 | RGL3 | RGL4 | RGMA | RGMB | RGMB-AS1 | RGN | RGP1 | RGPD1 | RGPD2 | RGPD3 | RGPD4 | RGPD4-AS1 | RGPD5 | RGPD6 | RGPD8 | RGR | RGS1 | RGS10 | RGS11 | RGS12 | RGS13 | RGS14 | RGS16 | RGS17 | RGS18 | RGS19 | RGS2 | RGS20 | RGS21 | RGS22 | RGS3 | RGS4 | RGS5 | RGS6 | RGS7 | RGS7BP | RGS8 | RGS9 | RGS9BP | RGSL1 | RHAG | RHBDD1 | RHBDD2 | RHBDD3 | RHBDF1 | RHBDF2 | RHBDL1 | RHBDL2 | RHBDL3 | RHBG | RHCE | RHCG | RHD | RHEB | RHEBL1 | RHEBP1 | RHEX | RHNO1 | RHO | Rho GTPase | Rho kinase (ROCK) | RHOA | RHOB